|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KRT6A |
Gene summary for KRT6A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KRT6A | Gene ID | 3853 |
| Gene name | keratin 6A | |
| Gene Alias | CK-6C | |
| Cytomap | 12q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0001897 | UniProtAcc | A0A0S2Z428 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3853 | KRT6A | CA_HPV_1 | Human | Cervix | CC | 1.14e-36 | -7.68e-01 | 0.0264 |
| 3853 | KRT6A | HSIL_HPV_1 | Human | Cervix | HSIL_HPV | 2.47e-22 | -7.24e-01 | 0.0116 |
| 3853 | KRT6A | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 1.03e-29 | -7.82e-01 | 0.0208 |
| 3853 | KRT6A | N_HPV_1 | Human | Cervix | N_HPV | 4.25e-16 | -6.31e-01 | 0.0079 |
| 3853 | KRT6A | N_HPV_2 | Human | Cervix | N_HPV | 2.93e-11 | 3.51e-01 | -0.0131 |
| 3853 | KRT6A | CCI_2 | Human | Cervix | CC | 1.37e-03 | 1.25e+00 | 0.5249 |
| 3853 | KRT6A | CCI_3 | Human | Cervix | CC | 1.62e-02 | 1.03e+00 | 0.516 |
| 3853 | KRT6A | Tumor | Human | Cervix | CC | 1.02e-113 | 1.34e+00 | 0.1241 |
| 3853 | KRT6A | sample3 | Human | Cervix | CC | 4.06e-94 | 1.25e+00 | 0.1387 |
| 3853 | KRT6A | H2 | Human | Cervix | HSIL_HPV | 1.28e-05 | -3.60e-01 | 0.0632 |
| 3853 | KRT6A | L1 | Human | Cervix | CC | 2.24e-03 | 4.64e-01 | 0.0802 |
| 3853 | KRT6A | T3 | Human | Cervix | CC | 6.77e-103 | 1.27e+00 | 0.1389 |
| 3853 | KRT6A | LZE11D | Human | Esophagus | HGIN | 2.57e-03 | 6.54e-02 | -0.005 |
| 3853 | KRT6A | LZE2T | Human | Esophagus | ESCC | 2.97e-13 | 2.83e+00 | 0.082 |
| 3853 | KRT6A | LZE3D | Human | Esophagus | HGIN | 1.01e-09 | 2.01e+00 | 0.0668 |
| 3853 | KRT6A | LZE4T | Human | Esophagus | ESCC | 7.90e-47 | 3.54e+00 | 0.0811 |
| 3853 | KRT6A | LZE7T | Human | Esophagus | ESCC | 6.26e-20 | 3.71e+00 | 0.0667 |
| 3853 | KRT6A | LZE8T | Human | Esophagus | ESCC | 8.73e-09 | 2.14e+00 | 0.067 |
| 3853 | KRT6A | LZE20T | Human | Esophagus | ESCC | 2.29e-27 | 3.04e+00 | 0.0662 |
| 3853 | KRT6A | LZE21D1 | Human | Esophagus | HGIN | 8.54e-05 | 1.27e+00 | 0.0632 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0042060111 | Skin | SCCIS | wound healing | 63/919 | 422/18723 | 2.26e-15 | 6.00e-12 | 63 |
| GO:0051701112 | Skin | SCCIS | biological process involved in interaction with host | 28/919 | 203/18723 | 7.55e-07 | 5.65e-05 | 28 |
| GO:0044403112 | Skin | SCCIS | biological process involved in symbiotic interaction | 35/919 | 290/18723 | 8.64e-07 | 6.24e-05 | 35 |
| GO:0052126112 | Skin | SCCIS | movement in host environment | 25/919 | 175/18723 | 1.52e-06 | 8.89e-05 | 25 |
| GO:0044409112 | Skin | SCCIS | entry into host | 22/919 | 151/18723 | 4.60e-06 | 1.94e-04 | 22 |
| GO:0052372110 | Skin | SCCIS | modulation by symbiont of entry into host | 10/919 | 49/18723 | 1.11e-04 | 2.37e-03 | 10 |
| GO:0043903112 | Skin | SCCIS | regulation of biological process involved in symbiotic interaction | 10/919 | 72/18723 | 2.61e-03 | 2.48e-02 | 10 |
| GO:004440328 | Skin | cSCC | biological process involved in symbiotic interaction | 126/4864 | 290/18723 | 6.39e-11 | 2.97e-09 | 126 |
| GO:005170129 | Skin | cSCC | biological process involved in interaction with host | 91/4864 | 203/18723 | 4.30e-09 | 1.45e-07 | 91 |
| GO:005212629 | Skin | cSCC | movement in host environment | 76/4864 | 175/18723 | 3.81e-07 | 7.55e-06 | 76 |
| GO:004206029 | Skin | cSCC | wound healing | 152/4864 | 422/18723 | 2.66e-06 | 4.26e-05 | 152 |
| GO:004440929 | Skin | cSCC | entry into host | 59/4864 | 151/18723 | 2.75e-04 | 2.22e-03 | 59 |
| GO:003582115 | Skin | cSCC | modulation of process of other organism | 43/4864 | 106/18723 | 7.14e-04 | 5.03e-03 | 43 |
| GO:005170216 | Skin | cSCC | biological process involved in interaction with symbiont | 39/4864 | 94/18723 | 7.37e-04 | 5.15e-03 | 39 |
| GO:004390325 | Skin | cSCC | regulation of biological process involved in symbiotic interaction | 31/4864 | 72/18723 | 1.21e-03 | 7.86e-03 | 31 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KRT6A | SNV | Missense_Mutation | rs369911781 | c.1081G>A | p.Glu361Lys | p.E361K | P02538 | protein_coding | deleterious(0.01) | benign(0.394) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| KRT6A | SNV | Missense_Mutation | c.1610N>A | p.Gly537Asp | p.G537D | P02538 | protein_coding | tolerated(0.05) | benign(0.071) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| KRT6A | SNV | Missense_Mutation | rs533157590 | c.44G>A | p.Arg15His | p.R15H | P02538 | protein_coding | tolerated(0.28) | benign(0) | TCGA-LD-A66U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| KRT6A | SNV | Missense_Mutation | novel | c.314N>A | p.Gly105Glu | p.G105E | P02538 | protein_coding | deleterious(0.02) | benign(0.154) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| KRT6A | SNV | Missense_Mutation | c.1502N>A | p.Ser501Asn | p.S501N | P02538 | protein_coding | tolerated(0.39) | benign(0.035) | TCGA-FU-A3TQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| KRT6A | SNV | Missense_Mutation | c.1117G>T | p.Asp373Tyr | p.D373Y | P02538 | protein_coding | deleterious(0) | possibly_damaging(0.787) | TCGA-FU-A3WB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| KRT6A | SNV | Missense_Mutation | novel | c.1278G>T | p.Lys426Asn | p.K426N | P02538 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KRT6A | SNV | Missense_Mutation | c.799N>G | p.Phe267Val | p.F267V | P02538 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| KRT6A | SNV | Missense_Mutation | novel | c.457N>A | p.Asp153Asn | p.D153N | P02538 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KRT6A | SNV | Missense_Mutation | rs758984854 | c.244N>A | p.Gly82Ser | p.G82S | P02538 | protein_coding | tolerated(0.15) | benign(0.005) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3853 | KRT6A | NA | TD101 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |